# Hikma Pharmaceuticals Plc 45.1% potential upside indicated by Deutsche

- Link: https://www.directorstalkinterviews.com/hikma-pharmaceuticals-plc-45-1-potential-upside-indicated-by-deutsche/4121163357
- Published: 2024-07-01T13:21:08+01:00
- Author: Charlotte Edwards

**[Hikma Pharmaceuticals Plc](https://www.directorstalkinterviews.com/ftse-company/hikma-pharmaceuticals/hik.l)**
with ticker (LON:HIK) now has a potential upside of 45.1% according to Deutsche.

HIK.LDeutsche set a target price of 2,750 GBX for the company, which when compared
to the Hikma Pharmaceuticals Plc share price of 1,895 GBX at opening today (01/07/
2024) indicates a potential upside of 45.1%. Trading has ranged between 1,711 (52
week low) and 2,222 (52 week high) with an average of 349,134 shares exchanging 
hands daily. The market capitalisation at the time of writing is £4,131,746,484.
Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities 
of the Company are the development, manufacture and marketing of a range of generic,
branded and in-licensed pharmaceutical products. The Company operates through three
segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals
across its markets with generic injectable products, supported by its manufacturing
facilities in the United States, Europe and Middle East/North Africa (MENA). The
Branded segment supplies branded generics and in-licensed patented products from
its local manufacturing facilities to retail and hospital customers across the MENA
region. The Generics segment supplies oral and other non-injectable generic and 
specialty products to the United States retail market, leveraging its manufacturing
facility in Columbus, Ohio. Its subsidiaries include Al Jazeera Pharmaceutical Industry
S.A.R.L, Hikma Pharma Algeria S.A.R.L. and others.

Share on: